Hi all,
SNT-5505: A Promising Treatment with Increasing Benefits Over Time.SNT-5505 continues to demonstrate exceptional promise in clinical trials. The latest interim data from its Phase 2 study highlights that the longer patients are exposed to SNT-5505, the greater the therapeutic benefits observed. This trend is particularly exciting as it suggests that extended dosing could lead to even better outcomes in future analyses.Improved Symptom Scores Over Time: At 12 weeks of treatment, 46% of patients achieved a 50% reduction in Total Symptom Score (TSS50), a key efficacy endpoint. Remarkably, this figure increased to 80% by 38 weeks, showcasing sustained and improving symptom relief with longer exposure.Clinically meaningful spleen volume reductions were observed, with 30% of patients achieving a ≥25% reduction (SVR25) and 20% achieving a ≥35% reduction (SVR35) at the 38-weekmark. These reductions continued to improve with time, even in patients with prior exposure to ruxolitinib.
SNT-5505 has been well-tolerated throughout the trial, with no treatment-related serious adverse events reported. This excellent safety profile further differentiates it from other myelofibrosis therapies currently available or in development worldwide.What sets SNT-5505 apart is its ability to deliver progressive improvements over time, unlike many existing treatments that plateau after an initial response. This suggests that longer dosing durations may unlock even greater benefits for patients. With additional interim data expected soon and final results anticipated later this year, the cat will be out of the bag.
The ability of SNT-5505 to modify underlying disease mechanisms rather than just mask symptoms positions it as a versatile therapeutic option across various fibrotic and hematological diseases.I am staying tuned for updates as Syntara prepares to advance toward pivotal trials and regulatory discussions.
Looking forward to more scientific discourse.
Kpax
Add to My Watchlist
What is My Watchlist?
